These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 23530114)

  • 1. Tumorigenic potential of circulating prostate tumor cells.
    Carvalho FL; Simons BW; Antonarakis ES; Rasheed Z; Douglas N; Villegas D; Matsui W; Berman DM
    Oncotarget; 2013 Mar; 4(3):413-21. PubMed ID: 23530114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients.
    Lustberg MB; Balasubramanian P; Miller B; Garcia-Villa A; Deighan C; Wu Y; Carothers S; Berger M; Ramaswamy B; Macrae ER; Wesolowski R; Layman RM; Mrozek E; Pan X; Summers TA; Shapiro CL; Chalmers JJ
    Breast Cancer Res; 2014 Mar; 16(2):R23. PubMed ID: 24602188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition.
    Gorges TM; Tinhofer I; Drosch M; Röse L; Zollner TM; Krahn T; von Ahsen O
    BMC Cancer; 2012 May; 12():178. PubMed ID: 22591372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EpCAM-Independent Enrichment of Circulating Tumor Cells in Metastatic Breast Cancer.
    Schneck H; Gierke B; Uppenkamp F; Behrens B; Niederacher D; Stoecklein NH; Templin MF; Pawlak M; Fehm T; Neubauer H;
    PLoS One; 2015; 10(12):e0144535. PubMed ID: 26695635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancer.
    Friedlander TW; Ngo VT; Dong H; Premasekharan G; Weinberg V; Doty S; Zhao Q; Gilbert EG; Ryan CJ; Chen WT; Paris PL
    Int J Cancer; 2014 May; 134(10):2284-93. PubMed ID: 24166007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients.
    Königsberg R; Obermayr E; Bises G; Pfeiler G; Gneist M; Wrba F; de Santis M; Zeillinger R; Hudec M; Dittrich C
    Acta Oncol; 2011 Jun; 50(5):700-10. PubMed ID: 21261508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential establishment of lung metastatic xenograft model of androgen receptor-positive and androgen-independent prostate cancer (C4-2B).
    Yamamichi F; Matsuoka T; Shigemura K; Kawabata M; Shirakawa T; Fujisawa M
    Urology; 2012 Oct; 80(4):951.e1-7. PubMed ID: 22920407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Negative enrichment by immunomagnetic nanobeads for unbiased characterization of circulating tumor cells from peripheral blood of cancer patients.
    Liu Z; Fusi A; Klopocki E; Schmittel A; Tinhofer I; Nonnenmacher A; Keilholz U
    J Transl Med; 2011 May; 9():70. PubMed ID: 21595914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epithelial cell adhesion molecule-positive circulating tumor cells as predictive biomarker in patients with prostate cancer.
    Amato RJ; Melnikova V; Zhang Y; Liu W; Saxena S; Shah PK; Jensen BT; Torres KE; Davis DW
    Urology; 2013 Jun; 81(6):1303-7. PubMed ID: 23622774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Novel Association of Circulating Tumor Cells and Circulating Megakaryocytes with Prostate Cancer Prognosis.
    Xu L; Mao X; Guo T; Chan PY; Shaw G; Hines J; Stankiewicz E; Wang Y; Oliver RTD; Ahmad AS; Berney D; Shamash J; Lu YJ
    Clin Cancer Res; 2017 Sep; 23(17):5112-5122. PubMed ID: 28615267
    [No Abstract]   [Full Text] [Related]  

  • 11. Microtube device for selectin-mediated capture of viable circulating tumor cells from blood.
    Hughes AD; Mattison J; Western LT; Powderly JD; Greene BT; King MR
    Clin Chem; 2012 May; 58(5):846-53. PubMed ID: 22344286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EpCAM-CD24+ circulating cells associated with poor prognosis in breast cancer patients.
    Perelmuter VM; Grigoryeva ES; Savelieva OE; Alifanov VV; Andruhova ES; Zavyalova MV; Bragina OD; Garbukov EY; Menyailo ME; Khozyainova AA; Denisov EV; Cherdyntseva NV; Tashireva LA
    Sci Rep; 2024 May; 14(1):12245. PubMed ID: 38806508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytometric characterization of circulating tumor cells captured by microfiltration and their correlation to the CellSearch(®) CTC test.
    Adams DL; Stefansson S; Haudenschild C; Martin SS; Charpentier M; Chumsri S; Cristofanilli M; Tang CM; Alpaugh RK
    Cytometry A; 2015 Feb; 87(2):137-44. PubMed ID: 25515318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A New Cell Block Method for Multiple Immunohistochemical Analysis of Circulating Tumor Cells in Patients with Liver Cancer.
    Nam SJ; Yeo HY; Chang HJ; Kim BH; Hong EK; Park JW
    Cancer Res Treat; 2016 Oct; 48(4):1229-1242. PubMed ID: 27034142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High detection rate of circulating tumor cells in blood of patients with prostate cancer using telomerase activity.
    Fizazi K; Morat L; Chauveinc L; Prapotnich D; De Crevoisier R; Escudier B; Cathelineau X; Rozet F; Vallancien G; Sabatier L; Soria JC
    Ann Oncol; 2007 Mar; 18(3):518-21. PubMed ID: 17322541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Use of a New CellCollector to Isolate Circulating Tumor Cells from the Blood of Patients with Different Stages of Prostate Cancer and Clinical Outcomes - A Proof-of-Concept Study.
    Theil G; Fischer K; Weber E; Medek R; Hoda R; Lücke K; Fornara P
    PLoS One; 2016; 11(8):e0158354. PubMed ID: 27479125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Filtration-based enrichment of circulating tumor cells from all prostate cancer risk groups.
    Awe JA; Saranchuk J; Drachenberg D; Mai S
    Urol Oncol; 2017 May; 35(5):300-309. PubMed ID: 28202223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumor cells exhibit stem cell characteristics in an orthotopic mouse model of colorectal cancer.
    Schölch S; García SA; Iwata N; Niemietz T; Betzler AM; Nanduri LK; Bork U; Kahlert C; Thepkaysone ML; Swiersy A; Büchler MW; Reissfelder C; Weitz J; Rahbari NN
    Oncotarget; 2016 May; 7(19):27232-42. PubMed ID: 27029058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis.
    Ramirez AB; Bhat R; Sahay D; De Angelis C; Thangavel H; Hedayatpour S; Dobrolecki LE; Nardone A; Giuliano M; Nagi C; Rimawi M; Osborne CK; Lewis MT; Stilwell JL; Kaldjian EP; Schiff R; Trivedi MV
    BMC Cancer; 2019 Mar; 19(1):220. PubMed ID: 30871481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epithelial-to-mesenchymal transition leads to disease-stage differences in circulating tumor cell detection and metastasis in pre-clinical models of prostate cancer.
    Lowes LE; Goodale D; Xia Y; Postenka C; Piaseczny MM; Paczkowski F; Allan AL
    Oncotarget; 2016 Nov; 7(46):76125-76139. PubMed ID: 27764810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.